Lymphopenia is detrimental to therapeutic approaches to type 1 diabetes using regulatory T cells

Keyphrases

• Therapeutic Approaches 100%
• Type 1 Diabetes Mellitus (T1DM) 100%
• Lymphopenia 100%
• Regulatory T Cells 100%
• Type I Diabetes 100%
• Interleukin-2 66%
• Treg 33%
• Regulatory T Cell(Treg) 33%
• Therapeutic Efficacy 33%
• Cytotoxic Cells 33%
• Immunomodulation 33%
• Selective Depletion 33%
• Fusion Protein 33%
• Adoptive Transfer 33%
• Caspase-3 33%
• Effector Cells 33%
• Pathogenic Cells 33%
• Regulatory T (Treg) Cells 33%
• NOD Mice 33%
• Effector T Cells 33%
• Therapeutic Design 33%
• Fas Ligand Protein 33%
• Inflammatory Insulitis 33%
• Physiological Recovery 33%
• Cellular Burden 33%

Medicine and Dentistry

• Insulin Dependent Diabetes Mellitus 100%
• Regulatory T Cell 100%
• Lymphocytopenia 100%
• Interleukin 2 66%
• Cytotoxic T-Cell 33%
• Rebound 33%
• Supplementation 33%
• Cytokine 33%
• T Cell 33%
• Immunomodulation 33%
• Fas Ligand 33%
• Caspase 3 33%
• Adoptive Transfer 33%
• NOD Mice 33%
• Effector Cell 33%
• Insulitis 33%
• Chimeric Protein 33%

Immunology and Microbiology

• Lymphocytopenia 100%
• Regulatory T Cell 100%
• Interleukin 2 40%
• Rebound 20%
• T Cell 20%
• Cytokine 20%
• Cytotoxic T-Cell 20%
• Immunomodulation 20%
• Caspase 20%
• Nonobese Diabetic Mouse 20%
• Effector Cell 20%
• Fas Ligand 20%